Biohope presents results of novel IVD solution in Rheumatoid Arthritis at EULAR Congress 2023
Biohope has presented a poster with clinical study results of the novel ROS and Monocytes tests to measure in vitro the methotrexate response in early rheumatoid arthritis patients at the European Congress of Rheumatology 2023 (EULAR), which took place in Milan on 31st May to 3rd June: “Precision Medicine in Rheumatoid Arthritis. Evaluation of two novel tests to predict clinical response to methotrexate in patients with early rheumatoid arthritis.”
The main goal of the clinical study was to measure in vitro the sensitivity to methotrexate in patients with new-onset rheumatoid arthritis and the association of methotrexate response with clinical remission at 6 months. 33 patients from 4 Spanish sites were included in this longitudinal, proof of concept study.
The study has shown that pharmacological response to methotrexate can be measured in vitro in naïve patients with new-onset rheumatoid arthritis by the quantification of total monocytes and ROS production from PBMCs. Low monocyte percentages and high levels of ROS production are associated with patients’ clinical remission at 6 months. Future studies are planned to validate these results.
